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1. Introduction  
Endometriosis is a common gynaecological disease, defined by the presence of endometrial 
tissue outside the uterus, causing pain and infertility of women in reproductive age (Galle, 
1989).  It is estimated that it occurs in 10-15% for women in the reproductive age and more 
than 30% of all infertile women are affected (Cramer et al., 2002).  However, the actual figure 
on the total prevalence may even be higher, as the disease is often not diagnosed due to 
heterogenous clinical manifestations. These manifestations include dysmenorrhoea, 
dyspareunia, dysuria and chronic abdominal or pelvic pain as well as infertility, resulting in 
a severely limited quality of life (Davis et al., 2003; Milingos et al., 2006; Vercellini et al., 
2007).  Thus, the aim on treating endometriosis should ideally target the endometriosis itself, 
i.e. relieves pain, promotes fertility and prevents reocurrence.  Unfortunately, there is no 
current treatment being able to fulfill all these requirements. All conservative treatments, 
either medical or surgical, are still liable for disease reocurrence, and they do not address the 
cause and possible side effects brought upon to the disease mechanism and the patient 
outcomes. 
In this chapter, we will analyze the rationale and limitations of the current therapy of 
endometriosis.  Also, we will discuss on the latest therapies that hold a higher efficacy and 
sensitivity on treating the disease.  Most importantly, we will highlight the effect of green 
tea on being a potential remedy toward tackling endometriosis. 
1.1 Current and new treatment 
In the past, the disease was best thought to be treated surgically. And with the advancement 
of operative laparoscopy, the treatment of endometriosis could be started as soon as it was 
diagnosis. However, different researches have shown surgical removal of endometriosis can 
bought upon many complications and chronicity. Likewise, without medical supplements, 
the patients would have a high chance for disease reocurrence. Hence, there is a great 
demand for medical treatments that can induce a suppression of this disease. 
The type of treatments offer would depend on the extent or stage of the disease, the amount of 
pain suffered, and fertility wanted (Valle et al., 2003) (Fig. 1). To perform the best therapy 
would require complete diagnosis and inspections of the lesion to determine the symptoms 
and staging of the patient’s endometriosis (Olive et al., 2001). The choices of present treatments 
include expectant management, medical therapy and surgical treatment (Table 1).  
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Traditional treatment
Expectant Management
Medical Therapy
- Analgesics 
- Hormonal 
- Selective progesterone receptor modulators
- Selective estrogen receptor beta agonists
- Gonadotropin releasing hormone antagonists
Surgical Treatment
- Conservative Surgery
- Definitive Surgery
 
New treatment 
Angiogenesis inhibitors
Antioxidant therapy
Aromatase inhibitors
Tumor necrosis factor-alpha inhibitors
Matrix metalloproteinase inhibitors
Immunomodulators
Traditional Chinese medicines
Table 1. Treatment of Endometriosis 
 
Fig. 1. Clinical evaluation on patients with endometriosis 
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1.1.1 Expectant management 
In asymptomatic patients, those with mild symptoms or infertility with minimal 
endometriosis, expectant management may be prescribed. These women may opt for birth 
control pills because they can prevent endometriosis from progressing and protect against 
unwanted pregnancy (Bedaiwy et al., 2009). While for women approaching the menopause, 
they may also be managed expectantly, because the growth of endometriosis is suppressed 
after the menopause. 
1.1.2 Medical therapy 
Medical therapies are typically used for patients with endometriosis that have minimal 
pelvic pain.  The types of medical therapies can be divided into two main categories: 
analgesics and hormonal. However, medical therapy alone is not appropriate for women 
with more advanced stages of endometriosis or those desiring pregnancy. And unlike 
surgery, medical therapy does not enhance your chances of conception (Hansen et al., 2006). 
1.1.2.1 Analgesics 
Analgesics treatments are often the first-line therapy in women with primary dysmenorrhea 
or pelvic pain and those with minimal pain symptoms associated with endometriosis. For 
mild cases of endometriosis, analgesic medications alone may be sufficient to relieve 
symptoms (Mahutte et al., 2003). Commonly used analgesic medications include 
paracetamol and non-steroidal anti-inflammatory drugs (NSAID). Although the use of 
analgesic treatments for pain relief is regularly prescribed, lack of clinical studies have 
critically evaluated their effectiveness. 
1.1.2.2 Hormonal  
Hormonal treatments are aimed at decreasing the amount of estrogen in the body, which 
will inhibit the progression of the endometrial implants (Coutinho, 1982). The most common 
hormonal medications used are combined oral contraceptives, progestins, androgens, and 
gonadotropin-releasing hormone (GnRH) agonist analogs. Combined oral contraceptives 
has been used for women with endometriosis since the 1950s (Kistner, 1959). These pills 
consist of a low combination of synthetic estrogen and progesterone. They have been shown 
to be very effective for patients with mild symptoms of endometriosis (Vercellini et al., 1993; 
Vessey et al., 1993). The main advantages are that it is inexpensive and is usually reasonably 
well tolerated by women (Kennedy, 2004). It can also be taken safely for many years if 
necessary (Kennedy, 2004). However, it is not free of side effects. These include irregular 
vaginal bleeding, fluid retention, abdominal bloating, weight gain, increased appetite, 
nausea, headaches, breast tenderness and depression. 
Progestins are a group of drugs that behave like the female hormone progesterone. Although 
the actual mechanism on how progestins relieve the symptoms of endometriosis remained 
unclear, a possible effect might be the growth of endometrial implants was suppressed by this 
hormone, causing them to gradually regress (Schweppe, 2001). Other reported that they may 
reduce endometriosis-induced inflammation in the pelvic cavity (Vercellini et al., 2003). In 
clinical trials, it showed progestins being effective treatments for the symptoms of 
endometriosis (Kennedy et al., 2005). When taken continuously daily, they have shown to 
relieve endometriosis-associated pain as effectively as the other hormonal drugs (Kennedy et 
al., 2005). However, there are side effects, which include irregular menstrual cycle, sore breasts, 
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headache, nausea, dizziness and bloating. These side effects are not usually serious and long-
lasting (Winkel et al., 2001), however many patients still feel unpleasant and difficult to cope 
with. Hence, most women could seldom complete this type of treatment. 
Danazol is an effective androgen for treating endometriosis. It works by suppressing the 
growth and development of the endometriotic lesion temporarily, hence continuous 
medication is required. Clinical trials have shown that danazol is effective in relieving the 
pain symptoms of endometriosis (Kennedy et al., 2005) for approximately 90% of women 
(Biberoglu et al., 1981). However, common side effects from these treatments include acne, 
oily skin, increased hair growth, and weight gain. Its unpleasant side effects and its risk of 
developing cardiovascular disease mean it is not the first choice of treatment for 
endometriosis (Kennedy, 2004). 
Gonadotropin releasing hormone (GnRH) agonists are a group of drugs that have been used 
to treat women with endometriosis for many years (Schweppe, 2005). They work by 
stopping the production of estrogen by a series of inhibition on the estrogen-related 
pathway mechanisms. Although this treatment can reduce 50% in symptoms, but in long-
term, pain recurrence can be observed in up to 75% of the cases (Surrey et al., 2002).  
Likewise, affecting the estrogen hormonal cycle can result in major side effects like bone 
thinning (Pierce et al., 2000). 
1.1.3 Surgical treatment 
Typically surgery becomes a choice after expectant management and hormonal therapy 
failed to reduce the patient symptoms (Olive et al., 2001; Winkel et al., 2001). Likewise, when 
anatomic distortions due to endometrial growths are present, surgery would also be the 
primary choice for treatment (Surrey et al., 2003). There are mainly two types of surgery 
associated with endometriosis: conservative and definitive. 
1.1.3.1 Conservative surgery 
This type of surgery is employed in cases of mild to moderate endometriosis, and for 
women who would like to retain fertility, as this surgery saves as much ovarian tissue and 
uterus as possible (Camanni et al.). The most common conservative surgical approach is the 
use of laparoscopy for treating endometriosis (Brosens et al., 1981). The aim of this type of 
surgery is restoration of the normal anatomy of the pelvis. Clinically, it has been shown that 
most patients, who undergone conservative surgery, realize a relief of pain symptoms 
associated with endometriosis. Women who had their implants excised had fewer 
symptoms 12 months (Abbott et al., 2004) and 18 months (Sutton et al., 1994; Sutton et al., 
1997) after surgery compared with women who underwent a laparoscopy without excision 
of their implants, respectively. However, this type of surgery has a high reoccurrence rate of 
up to 40% at 10 years post surgery.  
1.1.3.2 Definitive surgery 
On the other hand, patients suffering from painful symptoms resulted from severe 
endometriosis, and when fertility does not need to be retained, may require definitive 
surgery. This can involves the removal of the uterus (hysterectomy), fallopian tubes 
(salpingectomy), deep endometrial implants (debulking) and scar tissue (fibrinolysis). The 
ovaries may also be removed (oophorectomy) to prevent fluctuation of estrogen levels, 
which may cause any remaining endometrial implants to continue to grow. In such cases, 
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estrogen medication would be given to prevent menopausal symptoms to occur in the 
patients. Likewise, woman who underwent oophorectomy for endometriosis has greater 
pain relief and less likelihood of repeated surgery than those operated by hysterectomy with 
ovarian preservation (Namnoum et al., 1995). In addition, the rate of recurrence in patients 
with definitive surgery is much lower than in those with conservative surgery.  
1.1.4 Latest treatments developed against endometriosis 
Recently, with the better understanding on the pathogenesis and progression toward 
endometriosis, novel medications on using molecular targets are developed for treatment of 
endometriosis. The advantages of such agents hold a higher efficacy and sensitivity on 
treating the disease, while minimizing  evidence of side effects experienced by the patients.   
1.1.4.1 Anti-angiogenesis inhibitors 
One of the main etiologies of endometriosis is believe to be resulted from implantation of 
retrograde shed endometrium during menstruation (Sampson, 1927). The properties of the 
endometrium have the capacity to adhere, attach, and implant ectopically (Koks et al., 1999; 
Maas et al., 2001).  Based on the anatomical surrounding, endometriotic lesions are found to 
be larger in size with the availability to rich blood supply. This suggesting that angiogenesis 
is prerequisite for the development of endometriosis. 
The use of angiostatic agents may provide a new therapeutic option to inhibit this pathological 
process. The aim is to mainly control two processes involved in angiogenesis: endothelial cell 
growth and endothelial cell adhesion. Angiogenic cytokines are elevated in the peritoneal fluid 
in patients with endometriosis (Nisolle et al., 1993). Anti-angiogenesis therapies have been 
shown effective in suppressing the development in endometriotic lesion in mice (Nap et al., 
2004).  Common angiostatic compounds, such as anti-human vascular endothelial growth 
factor-A (anti-hVEGF), TNP-470, endostatin, and anginex,  significantly decreased microvessel 
density and inhibited the established endometriosis lesions (Dabrosin et al., 2002; Nap et al., 
2004; Yagyu et al., 2005). By far, the only clinical trial conducted with an anti-angiogenesis 
therapy on treating endometriosis-associated pain was thalidomide (Scarpellini et al., 2002).  
Although the result showed promising pain relief in the patients, however, thalidomide is a 
potential teratogen (Khoury et al., 1987). Thus, women wanting pregnancy is prohibited. 
1.1.4.2 Anti-oxidant therapy 
Although the actual etiology of endometriosis remains unknown, it is widely accepted that 
retrograde menstruation is associated with endometriosis. However, it is unclear on why 
only a portion of women with retrograde menstruation develops endometriosis, while 
others do not. Studies proposed this might be due to the presence of elements such as 
macrophages, iron or environmental contaminants disrupting the balance between ROS and 
antioxidants in the peritoneal fluid of some women, leading to oxidative stress and 
endometriosis (Arumugam et al., 1995; Donnez et al., 2002; Murphy et al., 1998). Likewise, 
the cyclical changes in the endometrium are accompanied by changes in the expression of 
various antioxidant enzymes in the endometrium (Gurdol et al., 1997). 
Patients with endometriosis have shown the increase in generation of ROS by peritoneal 
fluid macrophages, with increased lipid peroxidation (Halme et al., 1983). The diminished 
peritoneal fluid antioxidants (Murphy et al., 1998), elevated oxidized lipoproteins, 
lysophosphatidyl choline (Murphy et al., 1998), and other markers of lipid peroxidation 
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provide further evidence of oxidative stress in the peritoneal microenvironment of 
endometriosis (Ho et al., 1997; Szczepanska et al., 2003).  
Currently, a study investigated whether there would be reduced total chemokines and 
inflammatory cytokines in women with endometriosis (Santanam et al., 2003).  As patients 
were given 1200 IU of vitamin E and 1 g of vitamin C for a period of 2 months, this resulted 
in a decrease in the inflammatory markers monocyte chemotactic protein-1, regulated on 
activation normal T cell expressed and secreted (RANTES), and interleukin-6 in peritoneal 
fluid. Similar study showed these antioxidant supplements can reduce pelvic pain in 
women with endometriosis (Kavtaradze et al., 2003). 
Recently, an inhibitory drug has been used in clinical trials to determine the effect of anti-
oxidant therapy on endometriosis (Creus et al., 2008). Pentoxifylline, a phosphodiesterase 
inhibitor, has the capability to maintain a higher pregnancy rates in patients suffering from 
endometriosis. RU 486 exerts an inhibitory effect on endometrial cell growth through its 
antioxidant properties in vitro. Although antioxidants have shown to have beneficial effects 
in patients with endometriosis, the limited number of trials conducted questions the actual 
efficacy. 
1.1.4.3 Hormone inhibitors and modulators 
As endometriosis is an estrogen-dependent disease, the estrogen-related pathways are often 
the treatment used to tackle the imbalanced of estrogen in these female patients. A way is to 
suppress the production of estrogen by inhibiting its synthetic and regulatory pathway. 
Another potential way is to influence estrogen receptors minimizing estrogen-dependent 
gene expressions.  
Since aromatase, the key enzyme in estrogen synthesis in ovary, adipose tissue or 
endometriotic tissue, is encoded by a single gene, the inhibition of this gene or its 
production may cause an effective suppression of estrogen production (Simpson et al., 2002). 
Preliminary evidence suggests that combined treatment with luteinizing-hormone-releasing 
hormone analogues and aromatase inhibitors may be superior to medical treatment with 
luteinizing-hormone-releasing hormone analogues (Shaw, 1988). 
Another type of treatment is by using tumor necrosis factor alpha (TNF-α) inhibitor. This 
cytokine have been found to be overproduced in women with endometriosis, and partially 
responsible for the influx of peritoneal macrophages to occur in women with endometriosis 
(Montagna et al., 2008; Richter et al., 2005). A study was conducted to see the therapeutic 
effect on blocking this cytokine with recombinant human TNF binding protein-1 (TBP-1) in 
a baboon model (D'Hooghe et al., 2005). The result demonstrated the inhibition in the 
baboon, suggesting the effective in treating the manifestations of endometriosis.  However, 
there is currently no clinical study to determine the effect in human. 
1.1.4.4 Proteases 
Matrix metalloproteinases (MMPs) are a family of endopeptidases that play a role in the 
degradation and turnover of extracellular matrix proteins. Increased MMP activity has been 
described in endometriosis (Chung et al., 2002; Gottschalk et al., 2000).  There function is 
believed to be integral in the ability of endometrium to invade tissue and implant 
successfully. Inhibition of these enzymes might be effective in inhibiting the development of 
endometriosis. Yet, there is no in-depth study being reported thus raising uncertainty on the 
value and practicality of this approach. 
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1.1.4.5 Traditional Chinese medicines 
As surgical and hormonal treatment of endometriosis have unpleasant side effects and high 
rates of relapse, many patients began to explore more natural and traditional remedies. In 
China, treatment of endometriosis using Chinese herbal medicine is routine to alleviate 
pain, promote fertility, and prevent relapse.  Study showed post-surgical administration of 
Chinese herbal medicine may have comparable benefits to western medicines but with 
fewer side effects (Flower et al., 2009). In this study, it showed oral intake of traditional 
Chinese medicine have a better overall treatment effect than Danazol. Also, it is more 
effective in relieving dysmenorrheal and shrinking adnexal masses. Likewise, acupuncture 
is a new techniques employed to relieve the infertility  associated with endometriosis in 
women (Mo et al., 1993). However, due to the limited amount intervention studies reported, 
more rigorous researches are required to accurately assess the type, dose and potential role 
of Chinese herbal medicine in treating endometriosis. 
2. Anti-angiogenesis therapy 
2.1 Properties of anti-angiogenesis therapy 
Angiogenesis is the physiological process involving the growth of new blood vessels from 
pre-existing vessels.  It is a sequence of events that is fundamental to a broad array of 
physiological processes occurring in our body, including embryogenesis, development, the 
menstrual cycle and wound healing. Yet, it is also linked to many pathological situations 
such as cancer, chronic inflammation, ischemic diseases and endometriosis development 
(Griffioen et al., 2000). In general, the turnover of capillary endothelial cells is extremely 
slow in physiological angiogenesis. However, in the normal endometrium and in tumors, 
the turnover rate is altered to a more rapid state in promoting angiogenesis. Angiogenesis 
involve activation of angiogenic factors, dissolution of basement membranes by proteases 
derived from vascular endothelial cells, migration and proliferation of the endothelial cells, 
and capillary tube formation.  And various angiogenic factors are needed to regulate each 
step (Table 2). 
Under normal physiological conditions, angiogenesis is well controlled by the local balance 
between endogenous angiogenesis stimulators and angiogenesis inhibitors, although the 
regulatory mechanism is still not clear. During wound healing, the expression of vascular 
endothelial growth factor (VEGF), one of the most potent angiogenic stimulators, is 
significantly upregulated to promote wound healing by restoring blood flow to the injured 
tissues. As wound healing resolves, the expression of VEGF is downregulated and most 
angiogenic capillaries regress, resulting in a residual normal vascularity (Tonnesen et al., 
2000). Other studies indicates that a number of endogenous angiogenic inhibitors are 
present in the normal retina to balance the stimulatory effect of VEGF in the regulation of 
angiogenesis and vascular permeability (Ma et al., 2005). These studies suggest that 
endogenous angiogenic inhibitors can be used to balance the effect of angiogenic 
stimulators.  Anti-angiogenic therapies have already been experimentally proven to be 
effective in preventing metastasis and shrinking the established experimental tumors to be 
formed (Camp-Sorrell, 2003). Angiogenesis therapeutic approaches can be divided into two 
major classes: (1) interference with the process of neovascularization and (2) directly 
destroying immature blood vessels. 
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Interleukin-1 
Interleukin-6 
Interleukin-8 
Epidermal growth factor
Basic fibroblast growth factors
Insulin-like growth factors
Platelet-derived growth factor
Platelet-derived endothelial cell growth factor
Vascular endothelial growth factor
Endometriosis protein-I
Ovarian steroids
Estradiol 
Angiogenin 
Proliferin 
Pleiotropin 
Tumor necrosis factor-α
Hepatocyte growth factor
Transforming growth factor -α and -β
Placenta growth factor
Table 2. Angiogenic factors in endometriosis 
Although they may not necessarily directly kill tumor cells, angiogenesis inhibitors 
significantly enhance the efficacy of standard chemotherapy and radiation therapy by 
inhibiting tumor growth and tumor metastasis. Therefore, this type of therapy may need to 
be administered over a long period of time. In the normal healthy body, the process of 
angiogenesis is dormant and the angiogenesis switch is kept “off” with inhibitors being 
dominant over stimulators. Since anti-angiogenesis therapy is a targeted therapy aimed 
specifically at the angiogenic stimulators and the angiogenic microvascular endothelial cells, 
anti-angiogenesis therapy usually produces only mild side effects and is less toxic to most 
healthy cells. But as physiological angiogenesis is important in wound healing and 
reproduction, bleeding, blood clotting, heart function, the immune system, and the 
reproductive system, the unknown consequences on long-term treatment with anti-
angiogenic agents would still be a great concern (Board et al., 2006; Cabebe et al., 2007). 
2.2 Anti-angiogenesis potentials for endometriosis 
To date, endometriosis is often treated by hormonal medication, which aims at achieving a 
hypoestrogenic state. However, hormonal therapy would only suppress the symptoms 
associated with endometriosis, but not eradicating the ectopic implant. Moreover, 
significant side effects hinder the continuation of treatment (Saltiel et al., 1991). Long-term 
hormonal therapy, therefore, is not an attractive option. Alternatively, endometriosis can 
also be treated surgically. Conservative surgery consists of ablation of endometriosis lesions, 
resulting in pain relief, but high symptoms recurrence has been reported in a majority of 
patients (Vercellini et al., 2009). While definitive surgery includes removal of uterus, with or 
without ovaries, giving more permanent symptom relief, this therapy would result in the 
end of reproductive life. Therefore, an effective therapeutic agent for endometriosis would 
be a compound that not only prevents the development of endometriosis lesions, but would 
also be effective against the growth of established lesions. In cancer, endothelial cells have 
been shown to play a pivotal role in tumor cell survival and growth. In analogy with tumor 
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growth, endometriosis is shown to be highly dependent on angiogenesis, which makes the 
achievements in the field of cancer research applicable to endometriosis.  
Most of the studies on the role of angiogenesis in endometriosis have been performed in 
animal models so far. Still, more experiments are urgently needed to distinguish the effect of 
angiogenesis inhibitors on physiological and pathological angiogenesis. Like in a recently 
published study, the effect of angiogenesis inhibition was studied in nude mice. VEGF-A 
inhibitors were administered immediately after implantation of cultured human endometrium 
fragments (Hull et al., 2003). The results showed impaired lesion formation, which concluded 
that angiostatic agents may be effective in the treatment of endometriosis. And recently, 
encouraging results have been achieved with the use of Avastin, a humanized anti-VEGF 
antibody, on cancer. This approach of neutralizing VEGF provided the first proof of concept 
that anti-angiogenesis is applicable in humans (Ferrara, 2002; McCarthy, 2003). Yet, it still 
needs clinical trial to make a more concrete result on the anti-angiogenesis effect.  With prior to 
clinical testing to commence, the optimal mode of delivery and the best indication of anti-
angiogenic therapy would still need to be determined. However, the encouraging results of 
some anti-angiogenic drugs and the pressing need for new therapeutic approaches make 
angiogenesis an attractive novel target for the treatment of patients with endometriosis. 
2.3 Limitations 
The limitation of anti-angiogenesis therapy is that the patient’s immune system may be 
compromised (Calabrese et al., 2000). This would make the patient more susceptible to 
infection and delay wounds healing. In addition, patients may experience reproductive 
problems and damage to the fetus, if the patient was pregnant while taking the anti-
angiogenic drug. Other research has reported such therapy can enhance heart problems, 
elevating blood pressure and bleeding or blood clots could increase. Since angiogenesis 
inhibitor therapy is still under investigation, the definite possible complications and side 
effects are still unknown.  
3. Green tea and its clinical values 
3.1 Properties of green tea 
Tea (Camellia sinensis) is an aromatic beverage prepared from boiling or simmering of cured 
leaves. Apart from water, tea is one of the most popular consumed beverages worldwide, 
with a consumption of 120mL/day/capita (Graham, 1992).  Of the different varieties of tea, 
the most commonly found on the market are white, green, oolong and black tea. And over 
the last few decades, green tea has been subjected to many scientific and medical studies on 
its potential health beneficial effects (Table 3). 
 
Anti-aging 
Anti-bacterial 
Anti-inflammatory
Anti-angiogenic
Anti-cancer 
Lowering blood fat
Prevent tooth decay and clear bad breath
Enhanced skin whitening
Table 3. Benefits of green tea 
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Green tea contains polyphenols, particularly catechins, accounting for 30-40% of the dry 
weight (Balentine et al., 1997; Graham, 1992). The main components of green tea consist of 
catechins, minor flavanols and polymeric flavonoids (de Mejia et al., 2009). It contains more 
catechin concentrations than black tea or oolong tea, due to the minimal oxidation during 
processing. The compositions of green tea catechins are mainly comprised of (-)-epicathecin 
(EC), (-)-epigallocatechin (EGC), (-)-epigallocatechin gallate (EGCG), (-)-epicathecin gallatis 
(ECG), (-)-gallocatechin gallate (GCG), (-)-catechin gallate (CG) and (+)-cathecin (CT) (Miura 
et al., 1994) (Fig. 2). Among the components of green tea, (-)-epigallocatechin gallate (EGCG) 
is the most abundant and the most extensively studied catechin, accounting to 50-80% of the 
total catechins in green tea (Yang et al., 2002). 
 
Fig. 2. The main catechins components found in green tea 
3.2 Biological activities 
3.2.1 Anti-oxidant activity 
Free-radical damage has been postulated to contribute to the etiology of aging, and many 
chronic health problems such as cardiovascular, inflammatory diseases, and cancer (Rice-
Evans et al., 1993; Spiteller, 2001). The productions of free radicals, including reactive oxygen 
species (ROS), are capable of chemically altering many natural bio-molecules in our body, 
resulting in changes in their structure and function, leading to aging and the development of 
chronic diseases (McCall et al., 1999). 
Like most polyphenols, catechins and procyandins have an anti-oxidant activity. In a study 
conducted by Guo et al, ECG and EGCG displayed better antioxidant activity than EC and 
EGC on lipid peroxidation (Guo et al., 1996). Also, green tea catechins have been shown to 
protect or regenerate α-tocopherol in human low-density lipo-protein (LDL), which 
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functions as a major antioxidant in human LDL (Zhu et al., 1999). Similarly, EGCG and EGC 
show potent inhibitory effects on LDL oxidation in vitro, with EC and ECG being even more 
effective on protective activity on the depletion of α-tocopherol in LDL. And a clinical study 
claimed the consumption of 300 mg of green tea polyphenol extract twice daily for 1week 
can delayed the oxidation of human LDL ex vivo (Miura et al., 2000). 
3.2.2 Anti-mitotic 
Proliferation and migration of endothelial cells are major events in the angiogenic process 
for the formation of endometriosis. Matrix metalloproteinase-2 is expressed abundantly in 
lesions and has been suggested to play a key role in the degradation of the basement 
membrane, thereby promoting migration of endothelial cells (Zempo et al., 1994). Green tea 
polyphenols can significantly reduced endothelial cells proliferation in a dose-dependent 
manner and caused the accumulation of cells in the G1 phase without affecting cell viability 
(Kojima-Yuasa et al., 2003). In addition, EGCG suppressed endothelial cells proliferation and 
migration by inducing apoptosis through mitochondrial depolarization, activation of 
caspase-3 and reduction of binding of VEGF to its receptors in human ECs (Kondo et al., 
2002; Yoo et al., 2002). 
3.2.3 Anti-inflammatory 
Cytokines are a group of multifunctional proteins that mediate the regulation of 
inflammatory responses. These cytokines are expressed in a number of tissues, including 
macrophages, vascular endothelial cells, adipose tissue and neurons. In general, the role of 
cytokines can be further classified depending on the way they influence inflammation, such 
as pro- or anti-inflammatory (Kundu et al., 2008). Factors such as tumor necrosis factor-α, IL-
6, IL-1, GM-CSF, interferon-c, and IL-12 played a major role on the induction of the 
inflammatory response.  
EGCG has been shown to possess anti-inflammatory properties in vivo and in vitro (Hamer et 
al., 2007). The potent effects of tea polyphenols toward inflammation have also been known 
to cancer prevention (Beltz et al., 2006). Tea polyphenols appear to modulate at different 
targets the anti-inflammatory activities related to arachidonic acid-dependent pathways, 
such as cyclooxygenase (COX) inhibition. Within the arachidonic acid-independent 
pathways, nitric-oxide synthase (NOS) and nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) are targets of polyphenols (Miles et al., 2005). The released 
phytochemicals inhibit cyclooxygenase-2 (COX-2) and inducible nitric-oxide synthase 
(iNOS) expression by blocking NF-κB activation. Particularly EGCG suppresses activation of 
NF-κB by repression of degradation of inhibitory unit, IκBκ, which hampers subsequent 
nuclear translocation of the functionally active subunit of NF-κB (Kundu et al., 2008).   
3.2.4 Anti-angiogenic 
It has been widely shown that green tea have the ability to inhibit angiogenesis in in vitro 
proliferation studies (Laschke et al., 2008; Park et al., 2006; Slivova et al., 2005) and in in vivo 
angiogenesis assays (Laschke et al., 2008; Xu et al., 2009). Anti-angiogenesis plays a crucial 
role accounting to the cancer-preventive effect made by green tea. As angiogenesis is a 
complex multi-step process that includes the proliferation, migration and differentiation of 
endothelial cells into tube-like structures.  The initiation of each step involves multiple 
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growth factors, proteases and adhesion molecule secreted by the endothelial cells, as well as 
supporting cells from the surrounding (Carmeliet et al., 2000).  Pathogenesis related to 
abnormal angiogenesis can be demonstrated in rheumatoid arthritis, diabetic retinopathy, 
and cancer growth and metastasis. Therefore, angiogenesis would be a crucial process that 
may account for part of the mechanisms of the cancer preventive effect of green tea. Studies 
have shown green tea’s potential to decrease vital angiogenic factors in breast cancer  
(Sartippour et al., 2002; Sartippour et al., 2002).  Similarly, other showed the mark decrease of 
IL-8 production by endothelial cells (Tang et al., 2001).  Likewise, tumor necrosis factor-α 
and matrix metalloprotinases were suppressed by the incorporation of EGCG (Annabi et al., 
2002; Yang et al., 1998). The observation on the effect of green tea being anti-angiogenic is 
clinically very significant (Kabbinavar et al., 2003).  With the lack of information on clinical 
trials, work is still needed on promoting green tea as a possible medication on anti-
angiogenesis therapy. 
3.3 Side effects of green tea 
The preliminary efficacy results of a phase I–II clinical study from a cohort of non-cancer 
patients demonstrated no uncomfortable side effects (Choan et al., 2005).  To date, the only 
side effect reported from drinking green tea is to cause insomnia, increase heart rate and 
nausea in selected individual, due to the presence of caffeine. An average cup of tea (10 g of 
tea leaves in 1 L water) contains around 300 mg of crude solids with 30–42% catechins and 
3–6% caffeine (Khan et al., 2007). However, the amount of caffeine is three times less than 
that of drinking coffee.  Thus, this makes drinking green tea a prospective and very safe 
treatment for clinical use.   
4. Green tea for endometriosis 
As already proven, the catechins, notably EGCG, found in green tea are potential candidates 
to inhibit the growth of tumors (Jung et al., 2001; Nakachi et al., 1998; Uesato et al., 2001).  
They act as a pleiotropic substance, which influencing multiple mechanisms that are 
involved in carcinogenesis (Beltz et al., 2006; Khan et al., 2006) through suppressing 
angiogenesis (Kondo et al., 2002; Zhu et al., 2007).  With these basic finding, recent direction 
pointed out that the anti-angiogenic and anti-oxidation properties of ECGC may be a 
promising therapeutic agent in treating endometriosis. 
So far, there are two major groups studying the use of EGCG to relate with the inhibition of 
endometriosis (Laschke et al., 2008; Xu et al., 2009). In the study conducted by Laschke et al., 
the study showed that EGCG suppresses E2-stimulated activation, proliferation and VEGF 
expression of endometrial cells in vitro. While in the in vivo study using dorsal skinfold 
chamber model, EGCG selectively inhibited angiogenesis and blood perfusion of 
endometriotic lesions. Similarly, histology of the endometriotic lesion revealed induced 
regression when EGCG was prescribed.  The author proposed the possible mechanism on 
the inhibition on the growth of the lesion may be due to attenuation of VEGF expression by 
EGCG in cultured endothelial cells, with the stimulation with estrogen. This indicates that 
EGCG specifically blocks the E2-induced activation in endometrial cells, which EGCG 
would compete with E2 for binding to estrogen receptors.  In addition, the study found that 
EGCG treatment may not only induce regression of endometriotic lesions, but may also 
have a positive anti-angiogenic effect on the eutopic endometrium of endometriosis 
patients.  This was shown by the decrease in VEGF expression in the eutopic endometrium. 
www.intechopen.com
 
Green Tea for Endometriosis  
 
289 
Likewise, the possible toxicity by EGCG toward the reproductive organs was also 
investigated.  The treatment marked by EGCG showed no adverse effect neither on 
angiogenesis and blood perfusion nor tissue integrity of ovarian follicles.   
In another study conducted by our team, we demonstrated the anti-angiogenic effects of green 
tea catechin on a mouse model induced with endometriosis (Xu et al., 2009). These 
immunosuppressent mice were induced with endometriosis by subcutaneously implanting 
human endometrial tissues from patients with endometriosis. Following the day of operation, 
endometriosis induced mice were treated daily with saline, Vitamin E or EGCG for two weeks. 
The result showed those treated with EGCG, but not Vitamin E, have the smallest size of lesion 
growth. Angiogenesis in lesions from the implant and adjacent tissues was under-developed, 
and microvessel size and density were lower. With regards to the lower expression of VEGF 
expression, EGCG significantly inhibits the development of experimental endometriosis can be 
through anti-angiogenic effects.  Following on this study, we investigate the likely mechanism 
would involve the selective inhibition of angiogenic factors, mainly VEGF-C/VEGFR2 
pathway by EGCG to suppress the growth of the endometriotic lesions (Xu et al., 2011) (Fig 3). 
With these studies, the potential of green tea as an anti-angiogenic agent is high because of its 
low cost, wide availability, and apparent low toxicity. 
 
Fig. 3. Summary of the mechanism of green tea for endometriosis 
5. Conclusion 
Endometriosis is one of the most common benign gynaecological conditions.  It affects an 
estimated 176 million worldwide regardless to their ethnics and social background. And it is 
estimated that 30-40% of women with endometriosis may not be able to have children.  
However, there is currently no single etiology that can explain the pathogenesis and 
pleomorphic manifestations of endometriosis. 
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Current treatments for endometriosis remain unsatisfactory, owing to their focus on treating 
the symptoms rather than curing the disease.  In addition, each treatment proved to have 
many side effects (Rice, 2002).  Hence, there is a need to derive a new therapy to provide a 
more efficient and specific therapeutic alternatives to eliminate the lesions, while preventing 
reoccurrence and retaining fertility. 
To provide additional evidence to support the role of green tea in suppressing 
endometriosis, it would be an important future research goal. Several study areas should be 
emphasized. These areas include a more detailed molecular and cellular mechanism studies 
in animals and humans to verify the effects of green tea in humans, compared with those 
studied in animals. Next, the interactions between the green tea polyphenols and 
endometriosis have not been extensively investigated. This drawback can cause many 
important details being vague. Furthermore, the potential interactions of active compounds 
in green tea with other dietary active components and the roles of polymorphisms on the 
protective effects of tea need to be examined in future studies. Ultimately, clinical 
intervention trials should be conducted to verify the mechanisms of action of tea observed 
in animal studies in which tea does not show any unwanted side effect. 
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